Retatrutide is a new entry in the class of GLP-1 agonist drugs, which mimic an anti-diabetes/anti-obesity hormone called GLP-1 and keep levels up to 1,000 times higher than normal
Our products are designed for research use solely and are not approved for human consumption
Franck M, Tanner KT, Tennyson RL, Daunizeau C, Ferrucci L, Bandinelli S, Trumble BC, Kaplan HS, Aronoff JE, Stieglitz J, Kraft TS, Lea AJ, Venkataraman VV, Wallace IJ, Lim YAL, Ng KS, Yeong JPS, Ho R, Lim X, Mehrjerd A, Charalambous EG, Aiello AE, Pawelec G, Franceschi C, Hertel J, Flp T, Lemoine M, Gurven M, Cohen AA (2025) Nonuniversality of inflammaging across human populations
Younger adults were the most aware Adults aged 18-24 reported the highest awareness levels, with more than a quarter ( 25.92% ) saying they knew about the upcoming launch
Introduction With the surging popularity of GLP-1 medications such as [] Read More Relevant articles Helpful Links Copyright 2024 Bay Aesthetics
Patients should: Weigh themselves once weekly at the same time and under consistent conditions Record measurements in a diary or app to identify trends Aim for gradual weight loss (NHS advises 0.51 kg per week is generally safe and sustainable) Understand that response to GLP-1 therapy varies between individuals Report unexpected rapid weight loss or gain to their healthcare provider It is important to recognise that weight loss may plateau after several months, and this does not necessarily indicate treatment failure